Drugs / Disulfiram
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ANTABUSE | — | 1951-08-28 | fda.gov ↗ |
Trials 47 · a red edge is where a trial was stopped
1950195119521953195419551956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05162001 | Nov 2021 → Jan 2022 | obesity disorder | University of Guanajuato | Unknown | No outcome recorded |
| Phase 0 | NCT03151772 | Jan 2018 → Sep 2020 | glioblastoma | Sahlgrenska University Hospital | Terminated | No outcome recorded |
| Phase 0 | NCT01907165 | Oct 2013 → Nov 2016 | glioblastoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT06319872 | May 2025 → May 2029 expected | Stargardt disease, age-related macular degeneration, alcohol-related disorders, retinitis pigmentosa | University of Rochester | Recruiting | No outcome recorded |
| Phase 1 | NCT05210374 | Mar 2023 → Sep 2026 expected | sarcoma | Case Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04521335 | May → Dec 2021 | plasma cell myeloma | University of Utah | Terminated | No outcome recorded |
| Phase 1 | NCT02963051 | Jul 2017 → Dec 2018 | prostate cancer | Daniel George, MD | Terminated | No outcome recorded |
| Phase 1 | NCT02671890 | Feb 2016 → May 2024 | pancreatic adenocarcinoma, refractory malignant neoplasm | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT00742911 | Jul 2008 → Mar 2013 | cancer | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT00571116 | Sep 2006 → Aug 2012 | metastatic melanoma | University of California, Irvine | Terminated | No outcome recorded |
| Phase 1 | NCT00094289 | Aug 2004 → Jul 2005 | alcohol-related disorders | National Institute on Drug Abuse (NIDA) | Unknown | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT03891667 | Jul 2019 → Nov 2021 | — | Research Foundation for Mental Hygiene, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03198559 | Aug 2017 → Apr 2019 | HIV infectious disease | University of Melbourne | Terminated | No outcome recorded |
| Phase 1/2 | NCT02770378 | Nov 2016 → Oct 2018 | glioblastoma | University of Ulm | Completed | No outcome recorded |
| Phase 1/2 | NCT02715609 | Jun 2016 → May 2024 | glioblastoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01944371 | Sep 2013 → May 2014 | HIV infectious disease | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/2 | NCT00731133 | Aug 2008 → Sep 2010 | methamphetamine dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1/2 | NCT00729300 | Apr 2006 → Jun 2016 | cocaine dependence | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT00256230 | Jan 2002 → Aug 2007 | melanoma | John P. Fruehauf | Completed | No outcome recorded |
| Phase 216 trials | ||||||
| Phase 2 | NCT01777919 | Jan 2027 → Jan 2029 expected | glioblastoma | Olympion Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07534332 | May 2026 → Apr 2027 expected | obesity disorder, rheumatoid arthritis | University of Oklahoma | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07477457 | Mar 2026 → Mar 2028 expected | metastatic neoplasm, osteosarcoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04485130 | Aug 2021 → Feb 2022 | COVID-19 | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 2 | NCT04594343 | Nov 2020 → Sep 2021 | COVID-19 | ETICA | Completed | No outcome recorded |
| Phase 2 | NCT04265274 | Jan 2020 → Jan 2022 | breast cancer | National Cancer Institute, Slovakia | Withdrawn | No outcome recorded |
| Phase 2 | NCT03950830 | May 2019 → Sep 2021 | germ cell tumor | National Cancer Institute, Slovakia | Completed | No outcome recorded |
| Phase 2 | NCT03363659 | Mar 2018 → Jan 2022 | glioblastoma | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT03323346 | Sep 2017 → Oct 2025 | breast cancer | The Institute of Molecular and Translational Medicine, Czech Republic | Completed | No outcome recorded |
| Phase 2 | NCT03034135 | Mar 2017 → Jul 2018 | glioblastoma | Cantex Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02101008 | Mar 2010 → Feb 2013 | melanoma | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT00395850 | Apr 2007 → Dec 2011 | cocaine dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 2 | NCT00149630 | Jan 2005 → Dec 2009 | cocaine dependence, opiate dependence | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00913484 | Oct 2000 → Feb 2004 | cocaine dependence, opiate dependence | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00142844 | Sep 1999 → Mar 2005 | alcohol dependence, cocaine dependence | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT00000278 | Sep 1994 → Aug 1999 | alcohol-related disorders | Yale University | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02678975 | Jan 2017 → Jan 2021 | glioblastoma | Sahlgrenska University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00312819 | Mar 2006 → Dec 2009 | non-small cell lung carcinoma | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT02735577 | Mar 2016 → Oct 2019 | alcohol-related disorders | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT02134002 | Jun 2014 → Apr 2016 | cocaine dependence | Assistance Publique - Hôpitaux de Paris | Withdrawn | No outcome recorded |
| Phase 4 | NCT00721526 | Aug 2009 → Aug 2012 | alcohol dependence, anxiety disorder | University of New Mexico | Completed | No outcome recorded |
| Phase 4 | NCT00431262 | Feb 2007 → Jun 2009 | alcohol dependence | Psykiatrisk Center Gentofte | Unknown | No outcome recorded |
| Phase 4 | NCT00435435 | Sep 2000 → Apr 2005 | alcohol dependence | Finnish Institute for Health and Welfare | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT05667415 | Jun 2023 → Dec 2025 | — | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
| — | NCT01286259 | Jan 2011 → May 2014 | HIV infectious disease | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT01118741 | May 2010 → Jun 2012 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| — | NCT00580827 | Sep 2003 → Mar 2004 | opiate dependence | Yale University | Completed | No outcome recorded |
| — | NCT00002065 | — | HIV infectious disease | St. Vincent's Medical Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 8 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06793488 Background | Sep 2025 → Aug 2029 expected | alcohol-related disorders | Columbia University | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT00878306 Comparator | Nov 2008 → Apr 2013 | HIV infectious disease, substance abuse | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT00350870 Comparator | Apr 2005 → Dec 2010 | cocaine abuse | Yale University | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05626920 Comparator | May 2026 → Feb 2027 expected | inherited retinal dystrophy | University of Washington | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04502589 Comparator | Oct 2020 → Aug 2021 | alcohol-related disorders | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1/2 | NCT00745511 Comparator | Mar 2009 → Jun 2010 | macular degeneration | Ora Bio Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03714555 Comparator | Oct 2019 → Jul 2020 | malignant pancreatic neoplasm | HonorHealth Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00218608 Comparator | Apr 2001 → Jan 2007 | cocaine dependence, opiate dependence | University of Arkansas | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 58 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | disulfiram | “antabuse (disulfiram)” NCT00431262 ↗53 |
| Known as | Antabus | “Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase” NCT03323346 ↗ |
| Known as | Antabuse | “A recent article by Marikowsky and colleagues extended significantly our knowledge regarding the possible activity of disulfiram (well known in its commercial name Antabuse) as...” NCT00312819 ↗3“Disulfiram (Antabuse®) is a well-tolerated, cheap, generic drug that has been in use since the 1950s to treat alcoholism.” NCT02678975 ↗ “Although Disulfiram (Antabuse) is an approved drug to support the treatment of chronic alcoholism” NCT03950830 ↗ |
| Known as | Disulfirame | ChEMBL registry synonym — accepted as the source's own label CHEMBL964 ↗ |
| Known as | DSF | “Disulfiram (DSF) has been used for more than sixty years in the treatment of chronic alcoholism because of the unpleasant symptoms it provokes after ethanol intake.” NCT01777919 ↗5“Antifibrotic activity of DSF was investigated in kidney epithelial cells stimulated by transforming growth factor-β1 (5 ng/ml) as well as in two animal models.” PMID 35285015 ↗ Mar 2022 “Disulfiram (DSF) is a well-tolerated, inexpensive, generic drug” PMID 30647912 ↗ Nov 2018 “Disulfiram (DSF)” NCT05210374 ↗ “Disulfiram (DSF)” NCT00256230 ↗ “Disulfiram (DSF)” NCT07534332 ↗ |
| Known as | Esperal | ChEMBL registry synonym — accepted as the source's own label CHEMBL964 ↗ |
| Known as | NSC-25953 | ChEMBL registry synonym — accepted as the source's own label CHEMBL964 ↗ |
| Known as | ORA102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00745511 ↗ |
| Action | Inhibit | “By blocking the enzyme dopamine beta hydroxylase (DBH)” NCT00149630 ↗1“Aldehyde dehydrogenase inhibitor” CHEMBL964 ↗ |
| Modality | Small molecule | “the thiocarbamate molecule disulfiram” NCT00742911 ↗ |
| Route | Oral | “oral disulfiram” NCT00094289 ↗ |
| Target | ALDH2 | “Aldehyde dehydrogenase inhibitor” CHEMBL964 ↗ |
| Target | DBH | “By blocking the enzyme dopamine beta hydroxylase (DBH)” NCT00149630 ↗ |